EU Novel Food Regulation: Why NMN, Spermidine and Other Supplements Disappeared in 2026
Regulation 2015/2283 explained: how the EU decides which ingredients are 'novel foods', why NMN vanished from EU shelves, and what it means for brands selling across borders.
In 2023 many European supplement shoppers woke up to find NMN — the headline longevity ingredient of the previous two years — suddenly unavailable. The reason was not a safety scare and not a price change. It was a single paragraph in a 2015 EU regulation: if an ingredient was not consumed "to a significant degree" by humans in the EU before 15 May 1997, it is a novel food and requires pre-market authorisation. NMN never had that authorisation. Member state enforcement caught up, brands pulled stock, and the ingredient vanished overnight from mainstream EU retail. This article unpacks how Regulation 2015/2283 actually works, which supplements it has swept up in 2026, and why brands engineered for EU compliance from day one rarely feel these shocks.
The pattern has repeated with spermidine, with quercetin formulations, with monk fruit and with several emerging longevity molecules. Understanding the novel food process explains the strange rhythm of the EU supplement market — why some ingredients take five years to appear and others are allowed only for a single company. Nutrola's Daily Essentials, at $49/mo and EU certified, were designed specifically to sit on the authorised side of this regulation.
What Regulation 2015/2283 Actually Says
The 15 May 1997 Line
Regulation (EU) 2015/2283, replacing Regulation 258/97, defines as "novel" any food that was not used for human consumption to a significant degree within the EU before 15 May 1997. That date is arbitrary but absolute — it is the date the original novel-food law took effect. Ten categories of novel food are listed, including: new molecules, food from cell culture, food from material of mineral origin, food from plants/microorganisms/fungi/algae with no significant EU consumption history, and food using new production processes causing significant compositional change.
The Authorisation Process
A business submits an application to the European Commission. EFSA produces a safety opinion. The Commission issues an implementing act that authorises the food, sets conditions of use (dose, category, labelling) and — critically — grants five years of data protection, meaning only the applicant can benefit from proprietary scientific data during that period.
Generic authorisations open the ingredient to any manufacturer. Specific authorisations give market exclusivity to the applicant for five years.
The Supplements That Disappeared or Stalled
NMN (Nicotinamide Mononucleotide)
NMN was sold in the EU through grey channels until national food-safety authorities began enforcing the novel food classification. Multiple dossiers have been submitted to EFSA. Until the European Commission issues a positive implementing act, NMN cannot lawfully be placed on the EU market as a food or food supplement.
Spermidine
Spermidine as a concentrated extract (typically from wheat germ) has been the subject of novel food submissions. Whole wheat germ itself is of course traditional; the concentrated fraction marketed for its spermidine content is where the novel-food question arises. Authorisation status in 2026 is still evolving, with applications from specific companies receiving targeted authorisations in some cases.
Monk Fruit (Siraitia grosvenorii) Extract
Monk fruit extract was recognised as a novel food in the EU comparatively recently (2017 in the UK before Brexit, with EU authorisation following a separate track). The years-long delay meant monk fruit was widely used in US zero-calorie products long before it appeared in EU equivalents.
Quercetin at Concentrated Doses
Quercetin from fruit and vegetable sources is not itself novel. But isolated quercetin dihydrate at concentrated supplement doses has been the subject of EFSA scrutiny and novel-food positioning, particularly for specific isolation processes.
3-Hydroxybutyrate Salts (Exogenous Ketones)
Several ketone-salt and ketone-ester products — widely available in the US — have been held up by EU novel food procedures.
Table: Selected Novel Food Status (2026)
| Ingredient | Novel Food status | Submitting/authorised company | Authorisation year / status |
|---|---|---|---|
| NMN | Under assessment / not authorised | Multiple applicants | Pending as of 2026 |
| Spermidine (concentrated wheat germ) | Partial authorisations | Longevity Labs, others | Targeted authorisations issued |
| Monk fruit extract | Authorised | Layn Natural Ingredients and others | 2019+ |
| Astaxanthin (high-dose) | Authorised under specific conditions | Multiple | Authorised with max daily dose |
| Krill oil (Euphausia superba) | Authorised | Aker BioMarine | 2009 |
| Chia seeds | Authorised | Columbus Paradigm | 2009, extended scope later |
| Trans-resveratrol (synthetic) | Authorised as food supplement | DSM | 2016 |
| Iceberg / reduced nicotinamide riboside | Authorised | ChromaDex | 2017 |
| CBD (cannabidiol) | Not authorised as food | Hundreds of pending applications | Paused pending safety data |
These entries are drawn from the EU Novel Food Union List; consult the live list for authorisation conditions.
Why Brands Get Caught Out
The Pre-1997 Burden of Proof
A manufacturer claiming an ingredient is not novel must prove significant EU consumption before 15 May 1997 — often through trade records, invoices or historical product catalogues. For ingredients popularised after 2000, that evidence simply does not exist, and the ingredient is novel by default.
Post-Brexit UK Divergence
The UK retained the EU novel food framework under assimilated law but now processes applications through the Food Standards Agency. In principle this could lead to UK authorisations that diverge from EU decisions — early examples include certain CBD applications advancing further in the UK pipeline than in the EU.
Data Protection and the Five-Year Lock
When a specific applicant secures authorisation with five-year data protection, other manufacturers using proprietary data must wait. This is why some "novel" ingredients appear first only under a single brand. It is a legitimate regulatory incentive for companies to invest in safety data, not a loophole.
Consequences for Consumers
Supplements Appear and Disappear on Unpredictable Timelines
A compound validated by animal studies and early human data in the US may take five to ten years to reach EU shelves — if it reaches them at all. This partly explains why longevity and biohacking categories feel "US-first".
Grey Market Products Carry Real Risks
Products sold outside authorisation channels typically also sit outside routine food-safety inspection. That amplifies risk around heavy metals, microbial contamination and identity errors — precisely the problems GMP inspection is designed to catch.
Label Accuracy Benchmarks Differ
An authorised novel food carries specific labelling requirements (maximum daily dose, target population, warnings). An unauthorised product has no such obligations because, legally, it should not be on the market.
The Nutrola Approach
Nutrola was designed for EU compliance from day one. Daily Essentials, at $49/mo, uses only ingredients that are either long-established foods (vitamins and minerals on the Food Supplements Directive lists), or novel foods with existing EU authorisation at compliant dose levels. Manufacturing is EU certified and lab tested every batch.
The tracking app runs at €2.50/mo in 15 languages with zero ads, and tracks more than 100 nutrients including those with regulated upper intake levels. 4.9 stars, 1,340,080 reviews. When EU novel food enforcement tightens — as it has repeatedly since 2015 — the Nutrola formulation is unaffected.
Frequently Asked Questions
Why is NMN treated as novel but niacinamide is not?
Niacinamide (nicotinamide, vitamin B3) has been consumed in fortified foods and supplements in Europe for decades before 1997. NMN is a distinct metabolite with no comparable pre-1997 EU consumption record, placing it in the novel food category.
Does a novel food authorisation mean the ingredient is safe?
It means EFSA and the European Commission have reviewed the submitted dossier and concluded the ingredient is safe under the authorised conditions of use (specific dose, specific target population, specific source). Authorisation is conditional, not absolute.
Can UK and EU decisions differ after Brexit?
Yes. The UK retained the framework but operates its own regulatory body. Different timelines and — rarely — different outcomes are legally possible. Most authorisations so far have been congruent.
Is the novel food list the same as the banned substances list?
No. Novel foods are substances that require authorisation before sale. Banned substances cannot be sold at all. An ingredient may move from novel to authorised, remain pending for years, or be refused.
How long does novel food authorisation take?
From submission to implementing act, the published median is typically 18-30 months for straightforward dossiers and considerably longer for complex cases. CBD applications have been pending since 2019 due to safety data requests.
Citations
- European Parliament and Council. Regulation (EU) 2015/2283 on novel foods.
- European Commission. EU Novel Food Union List (consolidated regularly).
- EFSA Panel on Nutrition, Novel Foods and Food Allergens. Safety opinions on NMN, spermidine and related submissions.
- UK Food Standards Agency. Regulated products and novel foods guidance.
- European Commission. Implementing Regulation (EU) 2017/2470 establishing the Union list of novel foods.
- European Commission. Regulation (EU) 2017/2469 laying down administrative and scientific requirements for novel food applications.
Ready to Transform Your Nutrition Tracking?
Join thousands who have transformed their health journey with Nutrola!
